Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main goal of our investigation is to study the mechanisms of formation of left ventricular remodeling in patients with hypertension, working on a rotational expedition basis in the Arctic.
Hypothesis: In patients with hypertension working in the conditions of the Arctic shift, the combination of climatic and geographical factors and rotational expeditionary method of labor contributes to the increase in the left ventricular remodeling processes and leads to the formation of heart failure with preserved ejection fraction.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with hypertension of stages 1 and 2 | Individuals with stage 1 and 2 hypertension living in a temperate climate zone and doing rotational shiftwork in the Arctic. | ||
| Healthy volunteers | Virtually healthy individuals living in a temperate climate zone and and doing rotational shiftwork in the Arctic. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Echocardiographic assessment of GLS (Global longitudinal strain), % | Echocardiographic assessment of global strain (%) at baseline and after one year of follow-up. | One year |
| Measure | Description | Time Frame |
|---|---|---|
| Concentration of Myeloperoxidase, ug/mL | Concentration of oxidative stress biomarker, myeloperoxidase, is assessed using Lab analyzer Stat Fax 4200 (USA). | One year |
| Concentration of oxidized low density lipoproteins, CU |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Зatients with hypertension of stages 1 and 2 and practically healthy individuals living in a temperate climate zone and carrying out an Arctic watch. Hypertension in the Arctic is characterized by faster target organ damage and worse prognosis.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Liudmila Gapon, MD, PhD | Tyumen Cardiology Research Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tyumen Cardiology Research Center | Tyumen | Tyumen Oblast | 625026 | Russia |
Deidentified individual participant data (text, tables, figures, and appendices), underlying the results of the trial, will be shared with researchers to achieve the aims in the approved proposal.
Proposals may be submitted up to 36 months following publication of the results of the trial. After 36 months, the data will be available in the Center's data warehouse but without investigator support other than deposited metadata.
Information regarding submitting proposals and accessing data may be requested from the principal investigator by e-mail.
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Biomarkers of inflammation and biomarkers that allow to detect heart failure with preserved ejection fraction at an early stage
Concentration of oxidative stress biomarker, oxidized low density lipoproteins, is assessed using Lab analyzer - Stat Fax 4200 (USA).
| One year |
| Concentration of homocysteine, umol/L | Concentration of oxidative stress biomarker, homocysteine, is assessed using Lab analyzer - IMMULITE 2000 (Siemens Diagnostics, USA). | One year |
| Concentration of C-reactive protein, IU/L | Concentration of immune inflammation biomarker, C-reactive protein, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of tumor necrosis factor alpha, pg/ml | Concentration of immune inflammation biomarker, tumor necrosis factor alpha is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of 1,6,8 interleukins, pg/mL | Concentration of immune inflammation biomarker, (1,6,8) interleukin, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of GDF-15/MIC-1 (Growth Differentiation Factor 15/Macrophage-inhibitory 1), pg/mL | Concentration fibrosis biomarker, GDF-15/MIC-1, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of PIIINP (N-terminal propeptide to procollagen III), ng/mL | Concentration of fibrosis biomarker, PIIINP, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of FGF-23 (Fibroblast growth factor 23), pmol/L | Concentration of fibrosis biomarker, FGF-23, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of plasma procollagen type 3, CU | Concentration of remodeling factor biomarker, plasma procollagen type 3, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of adrenaline, pg/mL | Concentration of catecholamine, adrenaline, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of noradrenaline, pg/mL | Concentration of catecholamine, noradrenaline, is assessed using Lab analyzer - Stat Fax 4200 (USA); | One year |
| Concentration of testosterone, nmol/L | Concentration of hormone, testosterone, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of progesterone, nmol/L | Concentration of hormone biomarker, progesterone, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of estradiol, pg/mL | Concentration of hormone, estradiol, is assessed using Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of cystatin-C, ng/mL | Concentration of chronic kidney disease biomarker, cystatin-C, is assessed by Lab analyzer - Stat Fax 4200 (USA). | One year |
| Concentration of NGAL (Neutrophilic gelatinase-associated lipocalin or neutrophilic lipocalin), ng/mL | Concentration of chronic kidney disease biomarker, NGAL, is assessed by Lab analyzer - Stat Fax 4200 (USA). | One year |